FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Phase 2

Completed

Conditions: Aplastic Anemia

Interventions: Drug: cyclophosphamide
Biological: anti-thymocyte globulin
Drug: cyclosporine
Procedure: allogeneic bone marrow transplantation
Drug: methotrexate
Genetic: DNA analysis
Other: flow cytometry
Genetic: polymorphism analysis
Other: laboratory biomarker analysis

First Posted Date: 2006-06-23

Last Posted Date: 2017-04-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00343785

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Childhood Burkitt Lymphoma
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Anaplastic Large Cell Lymphoma
Childhood Chronic Myelogenous Leukemia
Chronic Phase Chronic Myelogenous Leukemia

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: ex-vivo umbilical cord blood expansion
Procedure: double-unit umbilical cord blood transplantation
Procedure: biopsy
Other: immunologic technique
Other: diagnostic laboratory biomarker analysis

First Posted Date: 2006-06-23

Last Posted Date: 2015-02-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00343798

Locations: 🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Phase 3

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Myelodysplastic Syndrome With Isolated Del(5q)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Previously Treated Myelodysplastic Syndromes
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: mycophenolate mofetil
Drug: cyclophosphamide
Drug: cyclosporine
Drug: busulfan
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Other: laboratory biomarker analysis
Genetic: cytogenetic analysis
Other: flow cytometry
Other: pharmacological study
Genetic: fluorescence in situ hybridization
Drug: tacrolimus
Genetic: polymorphism analysis
Drug: methotrexate

First Posted Date: 2006-05-04

Last Posted Date: 2014-10-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00322101

Locations: 🇺🇸
Weill Cornell University, New York, New York, United States
🇺🇸
HealthOne Presbyterian St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸
Emory University, Altanta, Georgia, United States

and more 5 locations

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes

First Posted Date: 2006-04-25

Last Posted Date: 2010-05-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00317785

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2006-04-25

Last Posted Date: 2015-10-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00317759

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia

Phase 1

Completed

Conditions: Fanconi Anemia

First Posted Date: 2006-04-25

Last Posted Date: 2012-04-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00317876

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇧🇷
Universidade Federal do Parana, Curitiba, Parana, Brazil
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2006-04-12

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00313625

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

Phase 1

Completed

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2005-11-04

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00248430

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Contiguous Stage II Grade 2 Follicular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Noncontiguous Stage II Grade 2 Follicular Lymphoma
Stage I Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Noncontiguous Stage II Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma

Interventions: Other: pharmacological study
Biological: rituximab
Drug: dexamethasone
Other: laboratory biomarker analysis

First Posted Date: 2005-10-27

Last Posted Date: 2017-05-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00244855

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2005-10-27

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00244829

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy